10
Participants
Start Date
November 14, 2024
Primary Completion Date
June 15, 2027
Study Completion Date
June 15, 2042
NRTX-1001
Biological: NRTX-1001 is an inhibitory neural cell therapy investigational product. It is derived from a human stem cell line that has been converted into high-purity inhibitory interneurons that produce GABA. NRTX-1001 is intended to persist long-term and not require repeated administration.
RECRUITING
SUNY Upstate Medical University, Syracuse
RECRUITING
UVA Health University Medical Center, Charlottesville
RECRUITING
Wake Forest Baptist Medical Center, Winston-Salem
RECRUITING
Duke University Hospital, Durham
RECRUITING
Atrium Health, Charlotte
RECRUITING
University of Iowa Health Care, Iowa City
RECRUITING
Medical College of Wisconsin, Milwaukee
RECRUITING
University of Chicago, Chicago
RECRUITING
University of Arkansas for Medical Sciences, Little Rock
RECRUITING
UTHealth Houston, Houston
RECRUITING
University of Colorado Anschutz Medical Campus, Aurora
RECRUITING
University of Southern California Keck Hospital, Los Angeles
RECRUITING
University of California San Diego, San Diego
RECRUITING
UC Irvine Medical Center, Orange
RECRUITING
University of California San Francisco, San Francisco
RECRUITING
Stanford University, Palo Alto
RECRUITING
Oregon Health and Science University, Portland
Lead Sponsor
Neurona Therapeutics
INDUSTRY